Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Anti-dsDNA antibody testing in the clinic: Farr or ELISA?

Nature Clinical Practice Rheumatology volume 3, pages 72–73 (2007)Cite this article

boxed-textNeogi T et al. (2006) Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 33: 1785–1788

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Riboldi P et al. (2005) Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 38: 39–45

    Article  CAS  Google Scholar 

  2. Haugbro K et al. (2004) Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 63: 386–394

    Article  CAS  Google Scholar 

  3. Forger F et al. (2004) Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 13: 36–44

    Article  CAS  Google Scholar 

  4. Renaudineau Y et al. (2006) Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum 54: 2523–2532

    Article  CAS  Google Scholar 

  5. Radice A and Sinico RA (2006) A new oligonucleotide-based ELISA for the detection of anti-double-stranded DNA antibodies. Autoimmunity 39: 113–119

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. M Mahler is Director of Development and Production of the Dr Fooke Laboratorien GmbH, Neuss, Germany,

    Michael Mahler

  2. MJ Fritzler is Professor of Medicine at the University of Calgary, AB, Canada.,

    Marvin J Fritzler

Authors
  1. Michael Mahler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marvin J Fritzler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marvin J Fritzler.

Ethics declarations

Competing interests

M Mahler is an employee and Scientific Director of Dr Fooke Laboraorien GmbH, Neuss, Germany.

MJ Fritzler is a paid consultant to ImrnunoConcepts Inc., Sacramento, CA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahler, M., Fritzler, M. Anti-dsDNA antibody testing in the clinic: Farr or ELISA?. Nat Rev Rheumatol 3, 72–73 (2007). https://doi.org/10.1038/ncprheum0398

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0398

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing